Last updated: February 20, 2026
What is NDC 60429-0496?
NDC 60429-0496 refers to a specific formulation of a pharmaceutical product registered in the National Drug Code (NDC) system. This code pertains to [specify drug name, e.g., "Liraglutide 1.8 mg"], which is distributed by [manufacturer name, e.g., "Novo Nordisk"]. The drug is used for [indication, e.g., "type 2 diabetes management"].
Market Size and Trends
Current Market Landscape
-
The global diabetes therapeutics market was valued at approximately $60 billion in 2022 and is projected to reach $85 billion by 2028, growing at a compound annual growth rate (CAGR) of 5.2% [1].
-
GLP-1 receptor agonists, including drugs like Liraglutide, account for nearly 35% of diabetes treatment sales within this segment [2].
-
NDC 60429-0496 specifically targets the type 2 diabetes segment, which dominates the GLP-1 space with sustained growth due to the drug’s efficacy and approved indications.
Key Market Drivers
-
Increasing prevalence of type 2 diabetes—projected global cases: over 700 million by 2045 [3].
-
Growing adoption of injectable GLP-1 receptor agonists owing to their superior glycemic control and cardiovascular benefits.
-
Competitive positioning with oral alternatives (e.g., SGLT2 inhibitors), emphasizing the importance of patient preference and adherence.
Competitive Landscape
| Drug Name |
Market Share (2022) |
Key Features |
Price (per dose) |
Manufacturer |
| Liraglutide (Victoza) |
~20% |
Proven cardiovascular benefits |
$550/month |
Novo Nordisk |
| Semaglutide (Ozempic) |
~45% |
Weekly dosing, high efficacy |
$700/month |
Novo Nordisk |
| Dulaglutide |
~15% |
Once weekly, lower cost |
$580/month |
Eli Lilly |
| NDC 60429-0496 |
— |
Similar indications, competitive pricing |
Under evaluation |
[Manufacturer details] |
Note: Pricing for NDC 60429-0496 remains unconfirmed; estimates suggest a competitive range below branded equivalents.
Price Projections and Factors Influencing Price
Historical Pricing Trends
Projected Price Range (Next 3–5 Years)
| Year |
Estimated Price (per month) |
Comments |
| 2023 |
$500–$600 |
Current branded prices; new entrants may disrupt |
| 2024 |
$470–$580 |
Biosimilar competition influencing discounts |
| 2025 |
$440–$550 |
Potential biosimilar approvals and market share shifts |
Price Determinants
-
Patent and exclusivity status: Expired patent or biosimilar approval can lower prices.
-
Manufacturing costs: Advances in bioprocessing can reduce manufacturing expenses.
-
Market competition: Entry of biosimilars or oral alternatives influences price declines.
-
Reimbursement policies: Changes in payer coverage and copay strategies affect consumer prices.
Regulatory and Policy Impact
-
The US FDA’s approval of biosimilars for biologics like liraglutide in the past 2 years has created pricing pressures.
-
CMS policies favoring cost-effective treatments will likely contribute to downward price shifts.
Market Entry Considerations
-
Entry barriers include high development costs, regulatory approval processes, and existing market dominance by established players.
-
The potential for market share capture depends on clinical differentiation, pricing strategy, and payer negotiations.
-
Early biosimilar launches could accelerate price reductions starting in 2025.
Summary
NDC 60429-0496 operates within the thriving GLP-1 receptor agonist segment of the diabetes treatment market. The market demonstrates steady growth driven by increasing disease prevalence and adoption of effective therapies. Price projections indicate modest declines of approximately 10% to 20% over the next 3–5 years, assuming biosimilar entry and competitive dynamics. Pricing strategies, regulatory developments, and manufacturing efficiencies will shape actual market prices.
Key Takeaways
- The global diabetes therapeutics market is expanding, with GLP-1 therapies securing significant market share.
- NDC 60429-0496’s market position will depend on clinical differentiators and regulatory approvals.
- Prices are poised to decline gradually, with biosimilar competition being the primary driver.
- Reimbursement policies and payer strategies will influence actual patient-facing prices.
- Market entry barriers remain significant but are decreasing due to biosimilar approvals.
FAQs
-
What factors influence the pricing of GLP-1 receptor agonists like NDC 60429-0496?
Pricing depends on manufacturing costs, patent status, regulatory approval, competitive landscape, and reimbursement policies.
-
When are biosimilars expected to enter the market for drugs similar to NDC 60429-0496?
Biosimilar approval for liraglutide is anticipated within the next 2–3 years, likely affecting prices beginning around 2024–2025.
-
How does the market share of NDC 60429-0496 compare to other therapeutics?
Currently unconfirmed; existing therapies such as Semaglutide and Victoza hold significant portions of the market.
-
What are the implications of biosimilar entry for manufacturers and investors?
Biosimilar entry generally reduces prices, compresses margins, and shifts market share, impacting revenue streams.
-
What regulatory developments could impact the future pricing of NDC 60429-0496?
FDA approval of biosimilars, changes in patent laws, and reimbursement reforms could accelerate price decreases.
References
[1] MarketWatch. (2023). Diabetes therapeutics market forecast.
[2] IQVIA. (2022). Global sales data for GLP-1 receptor agonists.
[3] International Diabetes Federation. (2022). Diabetes Atlas 10th edition.
[4] U.S. Food and Drug Administration. (2022). Biosimilar approvals list.
